Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

MustGrow Biologics (MGROF) Stock Price & Analysis

MGROF Stock Chart & Stats

$0.27-$0.01(-4.33%)
At close: 4:00 PM EDT
$0.25$0.33 Aug18 Aug2 Sep14 Sep29 Sep12 Oct27 Oct
Day’s Range
$0.26 - $0.27
52-Week Range
$0.22 - $0.68
Previous Close
$0.28
Volume
4,500
Average Volume (3M)
3,614
Market Cap
$18.15M
Enterprise Value
$20.73M
Total Cash (Recent Filing)
$4.37M
Total Debt (Recent Filing)
$515.57K
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Dec 01, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Modest leverage reduces near-term financial risk and limits interest-related pressure on cash flow. This gives MustGrow more balance-sheet flexibility than a highly indebted company while it works to improve commercialization, revenue scale, and operating performance.

Gross Margin

A roughly 53% TTM gross margin indicates that the underlying products can generate meaningful value above direct costs. Although overhead and operating expenses still drive large losses, this gross-profit foundation could support better earnings as revenue scale and commercialization execution improve.

Biologic Technology Model

MustGrow’s licensing-led model could provide a scalable route to commercialization without requiring a large direct-to-farm distribution operation. Partner manufacturing, registration, and selling may allow the company to monetize intellectual property across agricultural applications if regulatory and field validation progress.

Bears Say

Revenue Contraction

The sharp TTM revenue contraction shows that commercial momentum remains inconsistent and that the business has not yet established a dependable growth trajectory. Continued volatility can restrict operating leverage, weaken partner confidence, and make it harder to fund research and regulatory work internally.

Persistent Unprofitability

Large operating and net losses indicate that current revenue is insufficient to cover the company’s cost structure and overhead. Unless commercialization expands materially or expenses are reduced, ongoing losses can delay self-sustaining operations and increase pressure on future capital allocation.

Negative Cash Generation

Persistent negative operating and free cash flow means MustGrow is consuming cash rather than funding development from internal operations. That weakens financial durability and may increase reliance on external funding if regulatory, research, or commercialization expenses continue before revenue scales.

MustGrow Biologics News

MGROF FAQ

What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was $0.22 and its highest was $0.68 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is $18.15M.
When is MustGrow Biologics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MustGrow Biologics’s earnings last quarter?
MustGrow Biologics released its earnings results on Aug 27, 2026. The company reported $0 earnings per share for the quarter.
Is MustGrow Biologics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 70,441,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
MustGrow Biologics reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went up 5.296%.
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in MGROF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology